Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

Share Price is delayed by 15 minutes
Get Live Data
520.00    5.00 (0.97%)
Bid:
510.00
Ask:
530.00
Spread: 20.00 (3.922%)
Market Cap: £85.47m
ANP Live PriceLast checked at - London Stock Exchange

Intraday Anpario Share Chart

Full year trading statement

10 Jan 2025 07:00

RNS Number : 8294S
Anpario PLC
10 January 2025
 

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

 

 

Anpario plc("Anpario", the "Group" or the "Company")

 

Full year trading statement

 

Anpario plc (AIM:ANP), the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity, provides the following trading update for the year ended 31 December 2024 ("FY 2024"). The figures set out in this announcement remain subject to audit.

 

Trading update

The Group, including three months of trading for Bio-Vet Inc., delivered a stronger than expected operating performance in the second half of 2024. Year-end sales were higher than anticipated, and the Group now expects revenue for the 12 months ended 31 December 2024 to be approximately £37.5m* (31 December 2023: £31.0m). This strong performance in revenue combined with the Group's high operational gearing and favourable year-end foreign exchange movements, will result in adjusted EBITDA being ahead of current market expectations*.

 

Bio-Vet Inc. had a strong final quarter due to heightened demand for its products, which support the health of dairy cows affected by avian influenza, and our Middle East and Africa segment delivered an outstanding sales performance.

 

Financial position

Our financial position remains strong, with year-end cash balances of £10.5m* (31 December 2023: £10.6m), after accounting for the acquisition of Bio-Vet Inc. and associated land and buildings for an initial cash consideration of US$6.3m, on a debt-free basis, which completed in September 2024.

 

Our strong balance sheet enables the Group to invest in innovative natural product solutions, expand our global reach and explore earnings enhancing and complementary acquisitions to continue the profitable development of the Group. We remain confident in our ability to capitalise on growth opportunities, delivering long-term benefits to all stakeholders.

 

FY2024 Results

The Group expects to publish its FY 2024 final results on or around 26 March 2025.

 

 

 

*Analyst consensus for FY 2024 immediately prior to this announcement was Revenue of £35.25m, EBITDA of £5.7m and net cash of £7.2m.

 

Enquiries

 

Anpario plc

Richard Edwards, Chief Executive Officer

+44(0)7776 417 129

Marc Wilson, Group Finance Director

+44(0)1909 537 380

Shore Capital

 

(Nominated Adviser and Broker)

+44 (0) 20 7408 4090

Stephane Auton

Corporate Advisory

David Coaten

Tom Knibbs

Henry Willcocks

Corporate Broking

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUUUGUPAPWB
Date   Source Headline
21st Apr 20157:00 amRNSThe Queen's Award for Enterprise
16th Apr 20158:30 amRNSHolding(s) in Company
24th Mar 20154:24 pmRNSHolding(s) in Company
19th Mar 20154:51 pmRNSBlock Listing Application
18th Mar 20152:35 pmRNSHolding(s) in Company
17th Mar 20153:33 pmRNSIssue of Equity
10th Mar 20151:33 pmRNSDirector/PDMR Shareholding
4th Mar 20157:00 amBUSFinal Results
2nd Feb 20157:00 amRNSTrading Statement
23rd Jan 201510:00 amRNSBlocklisting Interim Review
8th Jan 20154:58 pmRNSHolding(s) in Company
14th Oct 20147:00 amRNSAgreement with Probiotics
6th Oct 20143:16 pmRNSTransaction in Own Shares
17th Sep 20144:31 pmRNSTransaction in Own Shares
11th Sep 20144:37 pmRNSDirector/PDMR Shareholding
10th Sep 20147:00 amBUSHalf-yearly Report
28th Aug 20144:20 pmBUSHolding(s) in Company
14th Jul 20143:02 pmRNSBlock Listing Application
14th Jul 20143:00 pmRNSBlock Listing Application
3rd Jul 20149:26 amBUSHolding(s) in Company
30th Jun 201410:55 amBUSHolding(s) in Company
25th Jun 20144:09 pmBUSHolding(s) in Company
24th Jun 20144:20 pmBUSResult of AGM
24th Jun 20143:36 pmBUSHolding(s) in Company
24th Jun 20147:00 amRNSTrading Statement
12th Jun 201412:03 pmBUSHolding(s) in Company
9th Jun 201411:54 amBUSDirector/PDMR Shareholding
5th Jun 201410:03 amBUSIssue of Equity
20th May 20143:12 pmBUSHolding(s) in Company
12th May 20147:00 amBUSAnnual Financial Report
15th Apr 20144:09 pmBUSHolding(s) in Company
9th Apr 20149:48 amBUSHolding(s) in Company
2nd Apr 20147:00 amBUSFinal Results
24th Feb 20147:00 amRNSAppointment of Peel Hunt as Nomad and Broker
3rd Feb 20147:00 amBUSTrading Statement
28th Jan 20147:00 amRNSDirector's Dealings
27th Jan 201412:06 pmBUSIssue of Equity
17th Jan 20145:10 pmBUSDirector/PDMR Shareholding
14th Jan 20144:39 pmBUSHolding(s) in Company
9th Jan 20147:01 amBUSDirector/PDMR Shareholding
9th Jan 20147:00 amRNSTrading in line with expectations
12th Dec 201310:07 amBUSHolding(s) in Company
6th Dec 20137:00 amRNSU.S. Office
28th Nov 20137:00 amRNSHolding(s) in Company
30th Oct 20133:27 pmRNSHolding(s) in Company
17th Oct 201312:45 pmBUSHolding(s) in Company
15th Oct 201311:31 amBUSHolding(s) in Company
14th Oct 20131:26 pmBUSHolding(s) in Company
30th Sep 20134:25 pmRNSIssue of Equity
27th Sep 20133:50 pmRNSDirector Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.